

From: Killion, Mark <MKillion@kadian.com>
Sent: Friday, December 11, 2009 6:40 AM
To: Allen, Benjamin; Askew, Richard; Connon, Sandra; Fitch, Shelley; Hepp, Christopher; Hight, Cecil; Rastovski, Cynthia; Romer, Lori; Sontag, John
Cc: Shepherd, Michael; Nathalie Leitch
Subject: Co-Pay Card Service Flash
Attachments: CH Service Flash v2 121009.pdf

Team,

As I mentioned Actavis is going to be sending a service flash to 36,000 pharmacies about the the co-pay card program being extended to 2010. Attached is a copy of that service flash. This lets pharmacies know to honor the co-pay cards in 2010 even if they have the expiration date of 12/31/2009. You can print this out and start showing it to your customers to let them know we will be continuing the program next year. I will let you know when we have more information about when the stickers with the new expiration date will be arriving. Thanks and please call me with any questions.

Mark

KADIAN® Morphine Sulfate Extended Release Capsules:

New NDC numbers for all strengths

Strength	Package Size	New NDC#
10 mg	100	46987-0410-11
20 mg	100	46987-0322-11
30 mg	100	46987-0325-11
50 mg	100	46987-0323-11
60 mg	100	46987-0326-11
80 mg	100	46987-0412-11
100 mg	100	46987-0324-11
200 mg	100	46987-0377-11

If you have any questions or problems re-ordering KADIAN®, please call our Customer Service line at **1-800-324-0836**

The KADIAN® Co-pay Assistance Program:

Extended through March 31, 2010

Actavis would like to inform you that the **expiration date for the KADIAN® co-pay assistance program has been extended from December 31, 2009 to March 31, 2010.** New co-pay assistance cards will be issued however cards stating the old expiration date will be accepted through March 31, 2010.

For more information, please call our Help Desk at **1-877-637-4629**

WARNING:

KADIAN® contains morphine sulfate, an opioid agonist and a Schedule II controlled substance, with an abuse liability similar to other opioid analgesics. KADIAN® can be abused in a manner similar to other opioid agonists, legal or illicit. This should be considered when prescribing or dispensing KADIAN® in situations where the physician or pharmacist is concerned about an increased risk of misuse, abuse or diversion.

KADIAN® capsules are an extended-release oral formulation of morphine sulfate indicated for the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time.

KADIAN® Capsules are NOT for use as a prn analgesic.

KADIAN® 100 mg and 200 mg Capsules ARE FOR USE IN OPIOID-TOLERANT PATIENTS ONLY. Ingestion of these capsules or of the pellets within the capsules may cause fatal respiratory depression when administered to patients not already tolerant to high doses of opioids. **KADIAN® CAPSULES ARE TO BE SWALLOWED WHOLE OR THE CONTENTS OF THE CAPSULES SPRINKLED ON APPLE SAUCE. THE PELLETS IN THE CAPSULES ARE NOT TO BE CHEWED, CRUSHED, OR DISSOLVED DUE TO THE RISK OF RAPID RELEASE AND ABSORPTION OF A POTENTIALLY FATAL DOSE OF MORPHINE.**

Please see full Prescribing Information for KADIAN® at www.kadian.com

WARNING:

KADIAN® contains morphine sulfate, an opioid agonist and a Schedule II controlled substance, with an abuse liability similar to other opioid analgesics. KADIAN® can be abused in a manner similar to other opioid agonists, legal or illicit. This should be considered when prescribing or dispensing KADIAN® in situations where the physician or pharmacist is concerned about an increased risk of misuse, abuse or diversion.

KADIAN® capsules are an extended-release oral formulation of morphine sulfate indicated for the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time.

KADIAN® Capsules are NOT for use as a prn analgesic.

KADIAN® 100 mg and 200 mg Capsules ARE FOR USE IN OPIOID-TOLERANT PATIENTS ONLY. Ingestion of these capsules or of the pellets within the capsules may cause fatal respiratory depression when administered to patients not already tolerant to high doses of opioids. **KADIAN® CAPSULES ARE TO BE SWALLOWED WHOLE OR THE CONTENTS OF THE CAPSULES SPRINKLED ON APPLE SAUCE. THE PELLETS IN THE CAPSULES ARE NOT TO BE CHEWED, CRUSHED, OR DISSOLVED DUE TO THE RISK OF RAPID RELEASE AND ABSORPTION OF A POTENTIALLY FATAL DOSE OF MORPHINE.**

WARNING:

KADIAN® contains morphine sulfate, an opioid agonist and a Schedule II controlled substance, with an abuse liability similar to other opioid analgesics. KADIAN® can be abused in a manner similar to other opioid agonists, legal or illicit. This should be considered when prescribing or dispensing KADIAN® in situations where the physician or pharmacist is concerned about an increased risk of misuse, abuse or diversion.

KADIAN® capsules are an extended-release oral formulation of morphine sulfate indicated for the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time.

KADIAN® Capsules are NOT for use as a prn analgesic.

KADIAN® 100 mg and 200 mg Capsules **ARE FOR USE IN OPIOID-TOLERANT PATIENTS ONLY.** Ingestion of these capsules or of the pellets within the capsules may cause fatal respiratory depression when administered to patients not already tolerant to high doses of opioids. **KADIAN® CAPSULES ARE TO BE SWALLOWED WHOLE OR THE CONTENTS OF THE CAPSULES SPRINKLED ON APPLE SAUCE. THE PELLETS IN THE CAPSULES ARE NOT TO BE CHEWED, CRUSHED, OR DISSOLVED DUE TO THE RISK OF RAPID RELEASE AND ABSORPTION OF A POTENTIALLY FATAL DOSE OF MORPHINE.**